By 1960 muscle relaxants were well established in anaesthesia. Tubocurarine was the drug of choice for operations of any significant duration, but because tubocurarine lasted around thirty minutes, gallamine was often preferred for shorter operations. This was despite gallamine causing tachycardia and a growing belief that it led to increased wound bleeding. Diallyl nor-toxiferine (alcuronium, Alloferin) was introduced by Hügin and Kissling in 1961. It was twice as potent as tubocurarine, caused less hypotension on induction and was soon widely accepted. However, it was not a dramatic departure from the available drugs.
In the late 1960s, Organon, at their research laboratory in Scotland, was manufacturing the oral contraceptive pill. They were seeking ways to expand their market and complement their ongoing research by finding non-hormonal uses for steroid-based drugs. A social encounter between David Savage, the chief medicinal biochemist at Organon, and Bill Bowman, a pharmacologist who had worked with Paton on curare-like drugs, led to an attempt to use steroid molecules in muscle relaxants. Paton and Zaimis had discovered that two choline-like molecules separated by 1nm were likely to cause neuromuscular block. Bowman suggested that Savage should use the rigid steroid molecule to fix acetylcholine molecules at the correct distance to achieve neuromuscular blockade. Clearly a skilful biochemist, David Savage achieved this with his first attempt and in 1968 he produced pancuronium.
Pancuronium was first used clinically by Baird and Reid in Glasgow in 1967. In their clinical trial they administered varying doses of pancuronium to six female patients having minor gynaecological procedures. The patients were all monitored with an electromyograph with recording electrodes over the hypothenar eminence. This appears to be the first clinical trial of a new relaxant that makes any reference to monitoring neuromuscular function. Unlike previous studies which had relied upon surgical relaxation, these patients were monitored until the twitch height had reduced to a flat line. The researchers defined the end-point of the relaxation as being when the twitch height had returned to pre-injection levels. Their small study suggested that pancuronium was about five times as potent as tubocurarine with a similar duration of action. There were no changes in blood pressure or pulse rate in any of their test patients and they concluded that further studies were required.
It was soon established that pancuronium had minimal ganglion-blocking and histamine-releasing properties which made it a valuable new relaxant. This was the era of heart valve surgery; rheumatic fever had become rare with the advent of antibiotics but had left a legacy of diseased valves requiring treatment. Pancuronium was the drug of choice for these operations. A study by Harrison in Sydney in 1972 compared tubocurarine, alcuronium, pancuronium and suxamethonium for cardiac surgery. He confirmed the general belief that "… the most convenient relaxant techniques consist of the use of pancuronium alone or preceded by suxamethonium.… It shares the advantage of suxamethonium that it does not cause a fall in arterial blood pressure but has the additional advantage that it does not have the arrhythmic properties of suxamethonium."
Pancuronium clearly had many advantages in compromised patients but it was still not the ideal drug. By 1974, cardiac surgery had changed its emphasis from valve surgery to coronary artery surgery. It was felt that pancuronium was potentially hazardous in these patients as it could raise both blood pressure and pulse rate and potentially lead to an increase in ischaemia.
By this time, David Savage had begun to appreciate the properties that anaesthetists required from a muscle relaxant. Presenters at the 1974 European Congress of Anaesthesiology were concerned about the vagolytic properties of pancuronium and, as a result, Dr Savage organized the 1st International Muscle Relaxant Symposium which was held at Westminster Hospital in London in 1975. It was attended by many prominent scientists and anaesthetists such as Bill Bowman, Ronald Katz, Stanley Feldman and Ronald Miller. By the conclusion of this meeting it was clear that a drug was required which had no cardiovascular effects at all.
Armed with this information, David Savage and his colleagues continued work on the steroid skeleton, varying the positions of the choline molecules. They were able to eliminate the cardiovascular effects of pancuronium with one of their structural modifications and set about designing a new series of drugs. The most successful of these, Org NC 45, was sent for clinical testing.
It was quickly established that Org NC 45 or vecuronium had all the attributes that the designers had intended. Savage and Baird summed up its properties in 1985 "Spontaneous recovery from muscle paralysis is predictably rapid and there is little evidence of cumulative effect following its administration over several hours by multiple injections or continuous infusion … Vecuronium is free from significant cardiovascular side-effects and, when twice the recommended intubating dose is given, the blood histamine levels remain within normal limits." They concluded "In comparison with the established neuromuscular blocking drugs, vecuronium would seem to represent a significant advance in that controlled relaxation can be readily maintained during surgical procedures extending in duration from some 20 minutes to many hours, without risk of prolonging recovery or unwanted side-effects."
The meeting held at Westminster Hospital in 1975 was a historic moment. It drew together a group of specialists to define the criteria for an ideal drug. What is even more remarkable is that this drug was produced to specifications and was available for clinical trials within five years. The creation of vecuronium and its important predecessor, pancuronium, was due to the efforts and enthusiasm of the Organon biochemist, Dr David Savage. But his work did not end there. He played a role in the development of rocuronium, a more recent advance in neuromuscular pharmacology and he was posthumously awarded the Pask Certificate of Honour by the Association of Anaesthetists of Great Britain and Ireland. He was remembered by Dr Leslie Baird: "David was an outstanding scientist and a delightful man with a wonderful sense of humour…. We worked together closely and there were many aminosteroid molecules drawn on many table napkins on aircraft and in hotels." C. BALL, R. N. WESTHORPE Geoffrey Kaye Museum of Anaesthetic History
